World Hepatitis Day 2026: Key Facts Everyone Should Know

Hepatitis is a global liver condition caused primarily by viral infection across five distinct strains (A, B, C, D, and E), as well as non-infectious causes such as heavy alcohol consumption, metabolic dysfunction, and autoimmune reactions. World Hepatitis Day is observed globally on 28 July, marking the birth date of Nobel Laureate Dr Baruch Blumberg, who discovered the hepatitis B virus. 

Quick Reads

• Massive Global Burden: Over 300 million people worldwide live with chronic viral hepatitis, leading to more than 1.3 million deaths each year, primarily due to cirrhosis and liver cancer.
• Distinct Transmission Routes: Hepatitis A and E spread through contaminated food and water via the fecal-oral route. Hepatitis B, C, and D spread through blood, semen, and other body fluids, including perinatal mother-to-child transmission.
• Diagnosis and Screening: Chronic hepatitis B and C are often completely asymptomatic until severe liver damage occurs, making proactive screening and routine blood tests essential.
• Curable and Preventable: Effective vaccines exist for Hepatitis A and Hepatitis B (which also confers immunity against Hepatitis D). Direct-acting antiviral therapies can cure over 95% of Hepatitis C infections within 8 to 12 weeks.

Every year on 28 July, health authorities, medical professionals, and patient advocacy groups observe World Hepatitis Day. This designated health awareness date was established by the World Health Assembly to bring international focus to viral hepatitis, a group of infectious diseases that affect hundreds of millions of individuals globally. The date honours Dr Baruch Samuel Blumberg, the American physician and geneticist who discovered the hepatitis B virus (HBV) in the 1960s and subsequently developed the first hepatitis B diagnostic tests and vaccines.

By understanding the distinct mechanics of liver inflammation and taking proactive preventive steps, communities can move closer to eradicating this preventable health crisis.

What is Hepatitis? Physiology and Pathophysiology

The term hepatitis is derived from the Ancient Greek word hepar (meaning liver) and the suffix -itis (meaning inflammation). In biological terms, hepatitis refers to any inflammatory condition affecting liver tissue. The liver is the largest internal organ in the human body and performs over 500 vital metabolic functions, including filtering toxins from the blood, synthesizing essential proteins and blood-clotting factors, storing vitamins and minerals, and producing bile to digest fats.

When the liver suffers an injury or viral attack, the immune system responds by deploying white blood cells to the organ. While this inflammatory response is intended to isolate and destroy pathogens, persistent or severe inflammation damages hepatocytes (liver cells). Over time, injured liver tissue forms fibrous scar tissue (fibrosis). If left untreated, progressive scarring replaces healthy liver architecture, leading to cirrhosis, impaired metabolic function, liver failure, and an elevated risk of liver cancer.

The Stages of Progressive Liver Damage

While viral infections represent the vast majority of hepatitis cases globally, the condition can also be triggered by non-infectious factors:

1. Alcohol-Related Hepatitis: Chronic, excessive alcohol consumption damages hepatocytes, causing fat accumulation, inflammation, and cellular death.
2. Toxic and Drug-Induced Hepatitis: Exposure to environmental toxins, industrial chemicals, or excessive dosages of specific medications (such as paracetamol) can induce acute liver injury.
3. Autoimmune Hepatitis: A chronic condition in which the body's immune system mistakenly identifies healthy liver cells as foreign threats and attacks them.
4. Metabolic Dysfunction-Associated Steatohepatitis (MASH): Formerly known as non-alcoholic steatohepatitis (NASH), this occurs when fat accumulates in the liver alongside inflammation, often tied to metabolic syndrome, obesity, and type 2 diabetes.

Detailed Breakdown of the Five Viral Strains

Viral hepatitis is caused by five distinct primary viruses, designated by the letters A, B, C, D, and E. Although they all affect the liver, these viruses belong to different biological families, exhibit different modes of transmission, and vary significantly in clinical outcomes.

Hepatitis A (HAV)

Hepatitis A is an acute, short-term virus transmitted primarily via the fecal-oral route. This occurs when an uninfected person ingests food or water contaminated with the feces of an infected person. It is commonly linked to inadequate sanitation, poor personal hygiene, and unsafe water supplies.

Unlike Hepatitis B and C, Hepatitis A does not cause chronic liver disease. The body's immune system typically clears the virus completely within a few weeks to a few months, conferring lifelong immunity. However, in rare instances, particularly among older adults or individuals with pre-existing liver disease, HAV can cause acute liver failure, which can be fatal. Safe, highly effective vaccines have been available for HAV since the 1990s.

Hepatitis B (HBV)

Hepatitis B is a major global health threat capable of causing both acute and chronic infection. The virus is highly contagious and spreads through contact with infectious blood, semen, or other bodily fluids. The primary modes of transmission include:

• Perinatal Transmission: Mother-to-child transmission during childbirth (the most common route in endemic regions).
• Unsafe Medical Injection Practices: Reusing syringes or unsterilized medical equipment.
• Sexual Transmission: Unprotected sexual intercourse with an infected partner.
• Percutaneous Exposure: Sharing personal care items like razors or receiving tattoos with unsterilized needles.

The age at which a person acquires HBV dictates the likelihood of chronic infection. Up to 90% of infants infected during their first year of life develop chronic hepatitis B, compared to less than 5% of adults infected in adulthood. Chronic HBV cannot be completely cured due to the persistence of viral genetic material inside hepatocyte nuclei, but it can be managed effectively with lifelong antiviral drugs that suppress viral replication and reduce liver cancer risk.

Hepatitis C (HCV)

Hepatitis C is a blood-borne virus that represents a leading cause of chronic liver disease, cirrhosis, and liver transplantation globally. Transmission occurs almost exclusively through direct blood-to-blood contact. Common exposure routes include the reuse of unscreened blood products, inadequate sterilization of medical equipment in healthcare settings, and the sharing of drug injection equipment.

Approximately 75% to 85% of individuals infected with HCV fail to clear the virus spontaneously and progress to chronic infection. Today, the medical landscape has been transformed by Direct-Acting Antiviral (DAA) medications. These oral, once-daily therapies achieve cure rates exceeding 95% with minimal side effects over an 8 to 12 week treatment course. Despite this medical breakthrough, there is currently no vaccine for Hepatitis C due to the high mutation rate of the virus.

Hepatitis D (HDV)

Hepatitis D, also known as the delta virus, is an incomplete RNA virus that requires the presence of Hepatitis B to replicate. Consequently, HDV infection can only occur in individuals who are already infected with HBV.

Infection can happen either as a simultaneous infection alongside HBV (coinfection) or as an added infection in someone already living with chronic HBV (superinfection). HDV-HBV superinfection is considered the most severe form of chronic viral hepatitis, as it accelerates the progression toward liver cirrhosis and liver failure. Because HDV depends entirely on HBV for its life cycle, universal immunization against Hepatitis B provides complete protection against HDV.

Hepatitis E (HEV)

Hepatitis E is primarily a water-borne infection transmitted via the fecal-oral route, frequently causing outbreaks in regions with limited sanitation and contaminated water supplies. It can also spread through the consumption of undercooked meat derived from infected animals, such as domestic pigs or wild boar.

In most individuals, Hepatitis E causes a self-limiting acute illness that resolves within two to six weeks. However, HEV poses a critical health risk to pregnant women, particularly during the third trimester, where it can cause acute liver failure with mortality rates reaching up to 20% to 25%. While a vaccine for Hepatitis E was developed and approved for use in China, it is not yet widely distributed internationally.

Clinical Symptoms: Acute vs. Chronic Presentation

Recognising the clinical signs of hepatitis is challenging because many symptoms are non-specific and overlap with common viral illnesses. Furthermore, chronic infections often produce no symptoms at all until the liver has sustained extensive irreversible structural damage.

Acute Phase Symptoms

When symptoms do appear during an acute infection, they generally manifest between two weeks and six months post-exposure:

• Systemic Symptoms: Low-grade fever, extreme fatigue, general malaise, joint aches, and muscle pain.
• Gastrointestinal Distress: Loss of appetite, nausea, vomiting, and mild abdominal discomfort located in the upper right quadrant beneath the ribcage.
• Classical Hepatic Signs: Jaundice (yellowing of the skin and whites of the eyes), dark or tea-colored urine, and pale or clay-colored bowel movements resulting from blocked bile secretion.

Chronic Phase Symptoms and Complications

Chronic hepatitis B and C can remain clinically silent for 10 to 30 years. As progressive inflammation causes ongoing liver cell death and fibrosis, patients may eventually experience:

• Chronic Fatigue: Persistent, unexplainable physical and mental exhaustion.
• Portal Hypertension: Increased blood pressure within the portal vein system due to scar tissue obstructing blood flow through the liver.
• Ascites: Accumulation of fluid within the abdominal cavity causing pronounced swelling.
• Oesophageal Varices: Enlarged, fragile veins in the esophagus or stomach that can rupture and cause life-threatening internal bleeding.
• Hepatic Encephalopathy: Cognitive impairment, confusion, or altered consciousness caused by the accumulation of toxins in the bloodstream that a failing liver can no longer filter out.

Comprehensive Prevention and Mitigation Strategies

Preventing the spread of viral hepatitis requires a combination of clinical immunisation programs, safe medical procedures, public health policies, and personal hygiene measures.

1. Immunisation Programmes

Vaccination represents the most effective barrier against viral hepatitis strains A and B.

• Hepatitis B Universal Birth Dose: The WHO recommends that all infants receive the hepatitis B vaccine as soon as possible after birth, ideally within 24 hours, followed by two or three subsequent doses to complete the primary series. This birth dose is crucial for preventing perinatal mother-to-child transmission.
• Hepatitis A Immunisation: Recommended for children, travelers visiting endemic countries, men who have sex with men, and individuals with pre-existing chronic liver conditions.

2. Blood Safety and Harm Reduction

Preventing blood-borne hepatitis strains B and C relies on strict infection control measures within healthcare settings and community support structures:

• Screening Blood Products: Mandatory universal screening of donated blood, tissue, and organs for HBV, HCV, and HIV markers before clinical use.
• Injection Safety: Transitioning fully to auto-disable syringes in healthcare facilities to prevent needle reuse.
• Harm Reduction Services: Providing sterile needle and syringe exchange programs alongside opioid agonist maintenance therapy for people who inject drugs.

3. Food and Water Sanitation

Mitigating the risk of food-borne and water-borne strains (HAV and HEV) requires robust municipal infrastructure and individual precautions:

• Access to safe, treated drinking water and proper sewage disposal infrastructure.
• Practicing consistent hand hygiene with soap and clean water, particularly before food preparation and after using sanitation facilities.
• Avoiding raw or undercooked shellfish, unpasteurised products, or street food prepared with untreated water in regions with poor sanitation.

4. Personal Hygiene and Sexual Health

Simple individual actions significantly lower the risk of viral exposure:

• Avoiding the sharing of personal grooming tools that might carry microscopic amounts of blood, such as razors, toothbrushes, hair clippers, or nail scissors.
• Ensuring that body art, piercing, and acupuncture facilities adhere to strict sterilisation techniques and use single-use, disposable needles.
• Practicing safe sex through the consistent use of barrier methods like condoms, particularly when engaging with new or multiple partners.

World Hepatitis Day and the Elimination Goal

In 2016, the World Health Assembly endorsed the Global Health Sector Strategy on Viral Hepatitis, which aims to eliminate viral hepatitis as a major public health threat by 2030.

World Health Organization 2030 Elimination Targets

Achieving these goals requires international funding, political commitment, decentralisation of screening services into primary healthcare networks, and reduction of medication costs through generic manufacturing.

Diagnosis, Medical Management, and Financial Preparedness

Diagnostic evaluation for hepatitis begins with routine blood testing. Initial liver function tests assess enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Elevated enzyme levels indicate active liver cell damage. Serological testing is then conducted to detect specific viral antigens or antibodies (such as HBsAg for Hepatitis B or Anti-HCV for Hepatitis C). If antibody tests are positive, viral load testing using polymerase chain reaction (PCR) assays confirms active viral replication.

For individuals diagnosed with chronic hepatitis B, long-term oral antiviral medications help suppress the virus and preserve liver tissue. For those with chronic hepatitis C, short courses of direct-acting antivirals offer a complete cure. Because managing chronic liver conditions involves ongoing diagnostics, specialist consultations, and costly therapies, having a comprehensive health insurance policy like those offered by Niva Bupa Health Insurance to cover diagnostic tests, regular screenings, and pre-existing conditions is crucial to safeguarding your physical and financial well-being.

Frequently Asked Questions (FAQs)

1. Is Hepatitis C completely curable?

Yes. Modern Direct-Acting Antiviral (DAA) medications can cure over 95% of Hepatitis C cases. These oral medications are taken daily for 8 to 12 weeks with minimal side effects, effectively clearing the virus from the body.

2. Can you have hepatitis without knowing it?

Yes, chronic Hepatitis B and Hepatitis C often produce no noticeable symptoms for 10 to 30 years. Many people only discover they have the infection during routine blood donation screenings or when symptoms of severe liver damage appear.

3. Which strains of hepatitis have effective vaccines?

Safe and effective vaccines exist for Hepatitis A and Hepatitis B. Because Hepatitis D requires Hepatitis B to survive, the Hepatitis B vaccine protects against Hepatitis D as well. There is currently no widely available vaccine for Hepatitis C.

4. How can a mother prevent passing Hepatitis B to her newborn baby?

A mother living with Hepatitis B can prevent passing the infection to her infant by ensuring the baby receives the Hepatitis B birth-dose vaccine within 24 hours of birth, along with Hepatitis B Immune Globulin (HBIG) where recommended.

5. What is the difference between Hepatitis A and Hepatitis C?

Hepatitis A spreads through contaminated food and water, causes an acute (short-term) illness, does not become chronic, and has a preventive vaccine. Hepatitis C spreads through blood-to-blood contact, becomes chronic in up to 85% of cases, lacks a vaccine, but can be cured with antiviral medications.